DISCLAIMER: THIS PAGE IS INTENDED FOR HEALTHCARE PROFESSIONALS IN Slovakia ONLY.
Information about the NuvaxovidTM XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601)
NuvaxovidTM XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601) has been granted full approval by the European Commission for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.
Report an Adverse Event (AE)
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system of Slovakia.
Štátny ústav pre kontrolu liečiv
Sekcia klinického skúšania liekov a farmakovigilancie
Kvetná ul. 11
SK-825 08 Bratislava 26
Tel: +421 2 507 01
e-mail: neziaduce.ucinky@sukl.sk
Tlačivo na hlásenie nežiaduceho účinku je na webovej stránke www.sukl.sk v časti Bezpečnosť liekov/Hlásenie o nežiaducich účinkoch.
Formulár na elektronické podávanie hlásení: www.portal.sukl.sk/eskadra
Contact Us
Tel: +421 2 330 579 30
09:00 - 17:00
Monday - Friday